Braak stage 1, 100% of pigmented neurons left
parkinsonconnecting

Gene record

OGFRL1

opioid growth factor receptor like 1

translation score 0.56, read 2026-10-18; 2 sealed predictions, 0 held; 2 receipts.

Six readers

readerfoundscore
genetics
Open Targets
genetic association 0.26 (overall 0.16)0.26
cell type
Human Protein Atlas
cell type enhanced, including astrocytes; strongest in schwann cells0.75
chemistry
Open Targets
a small-molecule pocket0.60
trials
ClinicalTrials.gov
no Parkinson's trials on record: an open field1.00
literature
PubMed
no papers tie it to Parkinson's yet1.00
pathways
Reactome
in no curated pathway0.00
proposal for OGFRL1, translation score 0.56

Knock down and overexpress OGFRL1 in astrocytes; measure a transcriptome-wide state shift (bulk RNA-seq) and α-synuclein uptake and degradation, and dopamine neuron survival in co-culture.

Cell type
astrocytes
Direction
Both arms: public data does not say which way helps.
Molecular readout
a transcriptome-wide state shift (bulk RNA-seq)
Functional readout
α-synuclein uptake and degradation, and dopamine neuron survival in co-culture
Rule-out
If neither arm moves a transcriptome-wide state shift (bulk RNA-seq) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
Lab request
CRISPRi knockdown and lentiviral overexpression of OGFRL1 in iPSC-derived midbrain astrocytes; n = 3 differentiations; readouts: a transcriptome-wide state shift (bulk RNA-seq); α-synuclein uptake and degradation, and dopamine neuron survival in co-culture. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.

Sealed predictions

  1. OGFRL1 in dopamine neurons, braak-0.09 (p 0.815) → -0.05 (p 0.892)receipt 2168
  2. OGFRL1 in astrocytes, braak+0.25 (p 0.520) → +0.18 (p 0.646)receipt 2167

Swarm cases

receipt 2168: OGFRL1 in dopamine neurons, braak

power
full sample -0.14 (p 0.573, n 18), 95% CI -0.57 to +0.35. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: -0.18 (p 0.476, n 18). does not hold up.
composition
dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.18 (p 0.465, n 18). could be the mix.
skeptic
leave-one-out range -0.27 to -0.07, sign flips 0; without severely affected donors -0.14 (p 0.573, n 18). fragile.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for OGFRL1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 2167: OGFRL1 in astrocytes, braak

power
full sample +0.22 (p 0.379, n 18), 95% CI -0.27 to +0.62. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: +0.23 (p 0.351, n 18). does not hold up.
composition
astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.21 (p 0.398, n 18). could be the mix.
skeptic
leave-one-out range +0.12 to +0.36, sign flips 0; without severely affected donors +0.22 (p 0.379, n 18). fragile.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for OGFRL1 in astrocytes.

case closed: nothing better to follow up.

Receipts

loading the receipts